SCHEMBL5140586

SCHEMBL5140586

CNC(=O)c1ccccc1NCc1cccc(C(F)(F)F)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 7/20 0.74
▸ ABL1 P00519 1/20 0.59
▸ EGFR P00533 1/20 0.59
▸ CSF1R P07333 1/20 0.59
▸ PDGFRB P09619 1/20 0.59
▸ KIT P10721 1/20 0.59
▸ FLT1 P17948 1/20 0.59
▸ FLT4 P35916 1/20 0.59
▸ KDR P35968 1/20 0.59
▸ KDM4E B2RXH2 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ RPS6KB1 P23443 3/20 0.54
▸ AURKA O14965 2/20 0.54
▸ AURKB Q96GD4 1/20 0.54
▸ MLYCD O95822 1/20 0.52
▸ TDO2 P48775 1/20 0.52
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ PLA2G1B P04054 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15528722 0.85 RXFP1 (1.00) RXFP1ABL1EGFRCSF1RPDGFRB
SCHEMBL1011471 0.85 RXFP1 (0.80) RXFP1ABL1EGFRCSF1RPDGFRB
SCHEMBL28644608 0.81 ADRA1D (0.58) RXFP1KDM4EALDH1A1MEN1KMT2A
SCHEMBL15529379 0.81 RXFP1 (1.00) RXFP1ABL1EGFRCSF1RPDGFRB
SCHEMBL1715715 0.76 KDR (0.68) RXFP1ABL1EGFRCSF1RPDGFRB
Hydrochloric Acid SCHEMBL27753364 0.76 RXFP1 (0.55) RXFP1EGFRKDM4ERPS6KB1AURKA
SCHEMBL28647447 0.76 ADRA1D (0.53) RXFP1ABL1EGFRCSF1RPDGFRB
SCHEMBL23864576 0.75 KMT2A (0.66) RXFP1MLYCDMEN1KMT2APLA2G1B
SCHEMBL4976103 0.75 KDR (1.00) RXFP1ABL1EGFRCSF1RPDGFRB
SCHEMBL29356168 0.75 KDR (1.00) RXFP1ABL1EGFRCSF1RPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 — — EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 — — EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 — — WO disclosed
Send feedback